HDAC8 inhibitor NBM-BMX

{
  "id": "MLC-T-ONC-014068",
  "term": "HDAC8 inhibitor NBM-BMX",
  "field": "Oncology and biomedicine",
  "definition": "An orally bioavailable inhibitor of histone deacetylase (HDAC) type 8 (HDAC8; HDAC-8), with potential antineoplastic activity. Upon administration, NBM-BMX targets and inhibits the activity of HDAC8. This results in an accumulation of highly acetylated chromatin histones, chromatin remodeling, and selective transcription of tumor suppressor genes, ultimately promoting cell-cycle arrest and induction of tumor cell apoptosis. HDAC8, a class 1 histone deacetylase, plays a key role in transcriptional regulation and cell cycle progression. Aberrant expression of HDAC8 or deregulated interactions with transcription factors may contribute to tumorigenesis. Isotype-selective HDAC inhibitors may be associated with fewer adverse effects compared to pan-HDAC inhibitors.",
  "synonyms": [
    "HDAC8i NBM-BMX"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/hdac8-inhibitor-nbm-bmx/"
}